Marking more than 15 years of partnership with Europe’s drug discovery community, Viva Biotech is reinforcing its dedication to the region through operational consistency, steady growth, and scalable collaboration. As the European biopharmaceutical sector undergoes major structural transformation, the importance of a dependable, long-term research partner has become increasingly critical to sustaining progress in key innovation initiatives.
Ensuring Stability in a Shifting Environment
Across Europe, clients see Viva Biotech as more than a service provider—they regard it as a trusted partner and an extension of their own teams. With a strong UK presence and specialized regional teams, the company delivers responsive, well-coordinated support throughout the complexities of the drug discovery process.
Ensuring Stability in a Shifting Environment
Across Europe, clients see Viva Biotech as more than a service provider—they regard it as a trusted partner and an extension of their own teams. With a strong UK presence and specialized regional teams, the company delivers responsive, well-coordinated support throughout the complexities of the drug discovery process.
- Consistent Foundation: Despite broader industry disruption, Viva Biotech has maintained stability, growing alongside its European partners for over 15 years.
- Local Expertise with Global Reach: Its UK base, combined with dedicated business development and project management teams, ensures hands-on support while seamlessly integrating global capabilities across cross-border projects.
- Trust-Driven Partnerships: In an industry where continuity is crucial, the company focuses on building long-term relationships through reliable delivery of scientific milestones year after year.
Driving Innovation Through Expanded Integrated Capabilities
To support partners in moving from early discovery to candidate selection with greater confidence, Viva Biotech continues to expand its platforms—positioning itself as a fully integrated partner across discovery, development, and manufacturing.
To support partners in moving from early discovery to candidate selection with greater confidence, Viva Biotech continues to expand its platforms—positioning itself as a fully integrated partner across discovery, development, and manufacturing.
- Comprehensive Scientific Integration: By combining Structure-Based Drug Discovery (SBDD), cryo-EM, and medicinal chemistry into a unified workflow, the company enables seamless progression from early discovery to lead optimization and candidate selection. Its expertise spans both traditional small molecules and emerging modalities such as peptides and proximity-inducing compounds.
- AI-Enhanced Discovery: Advanced AI-driven design tools are embedded within workflows, already contributing to nearly 200 projects by enabling faster, data-informed decision-making.
- Deep Structural Expertise: With experience covering more than 98,000 protein structures, over 200 cryo-EM structures, and 200+ membrane protein targets, partners benefit from strong technical insight.
- End-to-End Development Support: Extending into CMC and CDMO services, the platform bridges discovery and manufacturing, supporting projects through commercialization and process performance qualification. To date, this integrated model has advanced 295 drug programs at the CMC stage.
Shaping the Future of European Drug Discovery
The past 15 years in Europe have been marked by scientific excellence and strong, trust-based collaborations. Viva Biotech looks forward to continuing this journey, partnering with the next generation of innovators to drive future breakthroughs in drug discovery.
The past 15 years in Europe have been marked by scientific excellence and strong, trust-based collaborations. Viva Biotech looks forward to continuing this journey, partnering with the next generation of innovators to drive future breakthroughs in drug discovery.
]]>
